Search

everythinglearnresearchcommunity

for

Search:↓

Using tazarotene with GliSODin improves facial skin more than tazarotene alone.

SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

taVNS reduces vitiligo symptoms in mice.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Topical calcitriol may reduce hair loss from chemotherapy at higher doses.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

High S100A4 levels worsen glioblastoma by promoting blood vessel growth.

Lokivetmab reduced itching in a dog with skin lymphoma.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.

Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

The US and EU lead in cell and gene therapy regulations with more approvals and clinical trials, while India is in early stages with fewer approvals and expedited processes.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.